| Particulars (Rupees in Crores.) | Jun-2025 | Mar-2025 | Dec-2024 | Sept-2024 | Jun-2024 |
|---|---|---|---|---|---|
Gross Sales | 6,467 | 6,290.2 | 5,123.5 | 5,113.6 | 6,046.5 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 6,467 | 6,290.2 | 5,123.5 | 5,113.6 | 6,046.5 |
Other Operating Income | 106.7 | 237.7 | 145.6 | 123.4 | 161 |
Other Income | 154.9 | 80.6 | 57.5 | 68.5 | 63.2 |
Total Income | 6,728.6 | 6,608.5 | 5,326.6 | 5,305.5 | 6,270.7 |
Total Expenditure | 4,485.2 | 4,622 | 3,881.8 | 3,775.6 | 4,123.5 |
PBIDT | 2,243.4 | 1,986.5 | 1,444.8 | 1,529.9 | 2,147.2 |
Interest | 84.7 | 76.6 | 32 | 25.1 | 32.2 |
PBDT | 2,158.7 | 1,909.9 | 1,412.8 | 1,504.8 | 2,115 |
Depreciation | 238.1 | 237.9 | 229 | 233.6 | 215.3 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 230.7 | 990.6 | 39.3 | 365.6 | 653.8 |
Deferred Tax | 203.3 | -567.4 | 140.2 | 7.5 | -217.7 |
Reported Profit After Tax | 1,486.6 | 1,248.8 | 1,004.3 | 898.1 | 1,463.6 |
Minority Interest After NP | 54.2 | 72.8 | 2.7 | 9 | 62.6 |
Net Profit after Minority Interest | 1,466.8 | 1,170.9 | 1,023.5 | 911.2 | 1,419.9 |
Extra-ordinary Items | 0 | -89.49 | -0.3 | 0.3 | 0 |
Adjusted Profit After Extra-ordinary item | 1,466.8 | 1,260.39 | 1,023.8 | 910.9 | 1,419.9 |
EPS (Unit Curr.) | 14.58 | 11.64 | 10.17 | 9.06 | 14.11 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 100.6 | 100.6 | 100.6 | 100.6 | 100.6 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 34.68 | 31.58 | 28.19 | 29.91 | 35.51 |
PBDTM(%) | 33.38 | 30.36 | 27.57 | 29.42 | 34.97 |
PATM(%) | 22.98 | 19.85 | 19.6 | 17.56 | 24.2 |
Earlier this week, Zydus launched ‘VaxiFlu’, a trivalent influenza vaccine aligned with WHO guidelines, becoming the first Indian company to introduce such a vaccine.
The study, known as EPICS-III, tested the drug in adults with primary biliary cholangitis (PBC) a rare, progressive liver disease that often leaves patients with limited treatment options.
The company said it will work with the US regulator to resolve the points raised as quickly as possible.
This development comes after a USFDA inspection at one of Zydus' oncology facilities earlier this year.
In its filing with the bourses, Zydus informed that these observations received were minor, and not related to data integrity.
Here are some of the stocks that may see significant price movement today: Jio Financial Service, Hero MotoCorp, Abbott India, etc.
Here are some of the stocks that may see significant price movement today: Hindustan Copper, Maruti Suzuki, Zydus Lifesciences, etc.
For Zydus, this clean report adds a layer of credibility to its US compliance track record especially since the Ankleshwar facility is a key site for its API exports.
The acquisition is priced at $7.50 per share and will be completed in cash within 60 days, subject to regulatory approvals
It provides benefits such as faster approval, priority review and a more open line of communication with the F.D.A.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
